US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

19.14

-0.2098-1.08%

Post-market: 19.140.00000.00%19:30 EDT

Volume:127.96K

Turnover:2.44M

Market Cap:112.91M

PE:- -

High:19.20

Open:19.04

Low:18.87

Close:19.35

52wk High:21.50

52wk Low:14.38

Shares:5.90M

Float Shares:5.90M

Volume Ratio:2.99

T/O Rate:2.17%

Dividend:0.71

Dividend Rate:3.73%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

CSPC Pharmaceutical - Pharma's Sys6077 Injection Obtains Clinical Trial Approval in China

THOMSON REUTERS

Akeso Announces First Patient Enrolled in Global Phase Iii Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer

THOMSON REUTERS

Innovent Expands Phase 3 MarsLight-11 Trial of Ibi363/tak-928 to Include Non-Squamous NSCLC Patients

Innovent Announces Expansion of Global Phase 3 Marslight-11 Study of Ibi363/Tak-928 (Alpha-Biased Il-2/Pd-1 Bispecific Fusion Protein) in Immunotherapy-Resistant Nsclc to Include Patients with Non-Squamous Nsclc

THOMSON REUTERS

Hong Kong Stock Market Movers: CRO Sector Leads Gains as Citi Signals Positive Outlook for U.S. Licensing Policy Toward Chinese Drugmakers, Remains Bullish on Innovative Drugs and Biotech

Regulator Clarifies Insurers' Hong Kong Stock Connect ETF Investment Rules; Crealights' Southbound Stake Rises to 4.2%

CSPC Pharmaceutical Says Phase III Trial of Becotatug Achieves Positive Topline Results

CSPC Pharma's Phase III Trial of Lung Cancer Drug Combo Achieves Positive Topline Results

MT Newswires Live

WuXi Biologics - Wuxi Mashan Site Passes Two-Week FDA Gmp Inspection

THOMSON REUTERS

CSPC Pharma's JMT101 Combined with Osimertinib Achieves Positive Topline Results in Phase III Trial for First-Line Treatment of EGFR ex20ins NSCLC

CSPC Pharmaceutical - Phase Iii Trial of Becotatug (Jmt101) with Osimertinib Achieves Positive Topline Results

THOMSON REUTERS

CSPC Pharm Begins Phase III Breast Cancer Drug Trial

MT Newswires Live

CSPC Pharmaceutical - Pharma Initiates Phase Iii Trial of Hb1801 for Advanced Breast Cancer in China

THOMSON REUTERS

CSPC Pharmaceutical Group Stock Slips 3.2% in Hong Kong, Underperforms Competitors

Wuxi Biologics (Cayman) Stock Slips 1.7% in Hong Kong

Hong Kong Healthcare Stocks Show Resilience as CXO Sector Takes the Lead, Key ETF Closes Higher Despite Market Downturn, GenScript Hits Five-Year High, and Two Key Questions Emerge

INNOVENT BIO Posts Robust Growth on Dual Momentum From Oncology and Integrated Product Lines

Innovent to Present Phase 3 Interim Data for Cldn18.2 ADC Ibi343 in Third-Line Gastric Cancer at ESMO 2026

China's Innovative Drugs Take Center Stage at Global Lung Cancer Conference, with ADC Therapies Advancing to Earlier Treatment Lines

Hong Kong Stocks Open Mixed: Hang Seng Edges Down 0.09%, Tech Index Flat, Memory Chip Plays Surge

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/KURE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":19.14,"timestamp":1790971200000,"preClose":19.3498,"halted":0,"volume":127957,"hourTrading":{"tag":"盘后","latestPrice":19.14,"preClose":19.14,"latestTime":"19:30 EDT","volume":8,"amount":153.12,"timestamp":1790983803066,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.010842489328054955,"floatShares":5899036,"shares":5899036,"eps":0,"marketStatus":"Market Closed","change":-0.2098,"latestTime":"10-02 16:00:00 EDT","open":19.04,"high":19.2,"low":18.87,"amount":2436278.887525,"amplitude":0.017054,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":19.3498,"sharesOutstanding":4750002,"nav":19.06,"aum":112453199.16,"dividendRate":0.037315,"bidAskSpread":0.008807,"postHourTrading":{"tag":"盘后","latestPrice":19.14,"preClose":19.14,"latestTime":"19:30 EDT","volume":8,"amount":153.12,"timestamp":1790983803066,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.9854503635447447,"impliedVol":0.1722,"impliedVolPercentile":0.3665},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5899036,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.9854503635447447,"shares":5899036,"dividePrice":0.7142,"high":19.2,"amplitude":0.017054,"preClose":19.3498,"low":18.87,"week52Low":14.3797,"pbRate":"--","week52High":21.5,"institutionHeld":0,"latestPrice":19.14,"eps":0,"divideRate":0.037315,"volume":127957,"delay":0,"ttmEps":0,"open":19.04,"prevYearClose":17.04,"prevWeekClose":18.72,"prevMonthClose":19.25,"prevQuarterClose":19.25,"fiveDayClose":18.72,"twentyDayClose":18.91,"sixtyDayClose":16.4655},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670236882","title":"CSPC Pharmaceutical - Pharma's Sys6077 Injection Obtains Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236882","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236882?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:08","pubTimestamp":1790590137,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45I028:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1152091754.HKD","BK1515","IE00B543WZ88.USD","LU1152091168.USD","IE00B5MMRT66.SGD","LU0072913022.USD","LU1226288170.HKD","LU0140636845.USD","LU0880133367.SGD","LU1008478684.HKD","LU1813983027.USD","LU1226287529.USD","LU0314109678.HKD","IE00BZ08YR35.GBP","BK1191","IE00BZ08YT58.USD","LU1226287875.USD","LU0315179316.USD","LU0326950275.SGD","IE0008368742.USD","HK0000165453.HKD","LU2039709279.SGD","LU0501845795.SGD","IE0008369823.USD","SG9999004220.SGD","IE00B031HY20.USD","LU1226288253.USD","LU0067412154.USD","KURE","LU1960683339.HKD","LU1951186391.HKD","01093","LU1328277881.USD","LU1993786604.SGD","IE00BZ08YS42.EUR","BK1521","LU1807302812.USD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670400169","title":"Akeso Announces First Patient Enrolled in Global Phase Iii Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2670400169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670400169?lang=en_us&edition=fundamental","pubTime":"2026-09-28 10:05","pubTimestamp":1790561139,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nTUA2FCWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B5MMRT66.SGD","LU0348827113.USD","LU0348766576.USD","KURE","LU0348825331.USD","LU2476274308.USD","LU0348783233.USD","LU0417516738.SGD","LU1961090484.USD","BK1574","LU0417516571.SGD","LU0561508036.HKD","LU0348767384.USD","LU0540923850.HKD","LU0348784397.USD","LU2476274720.SGD","LU0634319403.HKD","LU2399975544.HKD","LU1794554557.SGD","LU1720050803.USD","LU2778985437.USD","LU0348735423.USD","09926","IE00BPRC5H50.USD","LU2488822045.USD","BK1161","IE00B543WZ88.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402351","title":"Innovent Expands Phase 3 MarsLight-11 Trial of Ibi363/tak-928 to Include Non-Squamous NSCLC Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402351?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:00","pubTimestamp":1790553625,"startTime":"0","endTime":"0","summary":"Innovent expands Phase 3 MarsLight-11 trial of IBI363/TAK-928 to include non-squamous NSCLC patientsInnovent Biologics expanded its global Phase 3 MarsLight-11 trial of IBI363/TAK-928 to include non-s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL8bvkF3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2097828714.EUR","LU2328871848.SGD","LU0455707207.USD","LU0326950275.SGD","01911","BK1583","HK0000165453.HKD","LU2242644610.SGD","LU2097828557.USD","LU2097828474.EUR","LU1188198961.HKD","LU0463099449.HKD","LU0149534421.HKD","LU0244354667.USD","LU0607220059.USD","LU2097828805.USD","LU0502904849.HKD","LU1969619763.USD","LU2488822045.USD","BK1147","KURE","LU2097828631.EUR","LU1831875114.USD","01801","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402334","title":"Innovent Announces Expansion of Global Phase 3 Marslight-11 Study of Ibi363/Tak-928 (Alpha-Biased Il-2/Pd-1 Bispecific Fusion Protein) in Immunotherapy-Resistant Nsclc to Include Patients with Non-Squamous Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402334?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:00","pubTimestamp":1790553600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nTUAQM6DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000165453.HKD","LU0244354667.USD","LU2097828474.EUR","LU0502904849.HKD","LU2328871848.SGD","LU2488822045.USD","LU1831875114.USD","BK1589","LU2097828631.EUR","LU2242644610.SGD","LU2097828557.USD","LU1188198961.HKD","LU0326950275.SGD","LU1969619763.USD","LU0463099449.HKD","LU0607220059.USD","LU2097828805.USD","BK1583","LU0455707207.USD","KURE","BK1161","LU0149534421.HKD","01801","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133697705","title":"Hong Kong Stock Market Movers: CRO Sector Leads Gains as Citi Signals Positive Outlook for U.S. Licensing Policy Toward Chinese Drugmakers, Remains Bullish on Innovative Drugs and Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=1133697705","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133697705?lang=en_us&edition=fundamental","pubTime":"2026-09-25 13:54","pubTimestamp":1790315655,"startTime":"0","endTime":"0","summary":"CRO-related stocks are among the top gainers, with GENSCRIPT BIO (01548) up 9.16% at HK$43.38, ASYMCHEM (06821) up 3.81% at HK$155.4, WUXI APPTEC (02359) up 2.44% at HK$210, WUXI BIO (02269) up 2.31%...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU0708995153.HKD","01548","BK1521","LU0516422440.USD","BK1576","SYNB","02359","LU0348735423.USD","LU0130102774.USD","LU2125910500.SGD","BK4207","LU1244550494.USD","LNGR","LU0072461881.USD","FTXO","BK1589","LU1242518857.USD","LU1046422090.SGD","LU1244550577.SGD","LU2417539215.USD","LU0648001328.SGD","LU0417516902.SGD","BK4588","LU0320765646.SGD","LU0823426308.USD","LU2236285917.USD","LU0979878070.USD","LU1074936037.SGD","LU0456827905.SGD","LU0348825331.USD","LU0098860793.USD","LU1668664300.SGD","LU2456880835.USD","159837","LU0029874905.USD","LU0456846285.SGD","HK0000320264.USD","HK0000320223.HKD","LU0348766576.USD","LU0823426480.USD","SG9999002562.SGD","HBImain","LU0856984785.SGD","BK4585","LU0181495838.USD","IBBQ","LU0516423174.USD","BK4559","LU0043850808.USD","TFNS","LU1267930227.SGD","MEDX","LU0359201612.USD","LU1201861249.SGD","LU0516423091.SGD","LU1506573853.SGD","LU1720050803.USD","HK0000306685.HKD","SG9999002463.SGD","LU0052756011.USD","LU0051755006.USD","LU0052750758.USD","LU3063872942.SGD","LU0348767384.USD","LU0162691827.USD","LU0348827113.USD","LU0561508036.HKD","02269","LU0588546209.SGD","LU0708995583.HKD","LU1366192091.USD","LU2242644610.SGD","LU0634319403.HKD","LU2125154778.USD","IE00B0JY6N72.USD","LU0310800965.SGD","XBI","LU1880383366.USD","LU0106831901.USD","BK1141","LU0417516738.SGD","03347","GDOC","LU0128525689.USD","BK4566","BK1574","06978","BK4534","LU2125154935.USD","LU0469268626.HKD","LU1244550221.USD","LU1794554557.SGD","LU0128522744.USD","IEIH","LU0327786744.USD","LU2045819591.USD","LU0540923850.HKD","C","AGNG","LU0203345920.USD","LU1162221912.USD","BK1191","VXUS","LU0029874061.USD","LU0326950275.SGD","LU0140636845.USD","LU0320764243.SGD","LU0516422366.SGD","BK1583","LU0516422952.EUR","LU0307460666.USD","IE00BSNM7G36.USD","LU0170899867.USD","BK4581","06821","LU0128526141.USD","LU0819121731.USD","LU0130517989.USD","LU1791807156.HKD","BK1610","IYF","LU1144417596.USD","BK1161","IBBJ","LU2360032135.SGD","HK0000306701.USD","LU0980610538.SGD","LU1242518931.SGD","LU1688375341.USD","LU0320764599.SGD","LU0477156953.USD","KCAI","LU0203347892.USD","159992","LU2039709279.SGD","LU2462157665.USD","LU0314106906.USD","LU0039217434.USD","LU0572944931.SGD","LU0359202008.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171106151","title":"Regulator Clarifies Insurers' Hong Kong Stock Connect ETF Investment Rules; Crealights' Southbound Stake Rises to 4.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171106151","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171106151?lang=en_us&edition=fundamental","pubTime":"2026-09-25 08:12","pubTimestamp":1790295146,"startTime":"0","endTime":"0","summary":"Several insurers recently received a letter clarifying the regulatory scope for insurance funds investing in Hong Kong Stock Connect ETFs. The document specifies that insurance institutions eligible...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU1206782309.USD","LU1226287792.SGD","BK1515","LU1993786604.SGD","LU0315179316.USD","LU0320764599.SGD","LU2257852520.SGD","LU2097828474.EUR","BK1184","LU1813983027.USD","LU1152091754.HKD","SG9999012710.SGD","BK1170","BK4550","LU0307460666.USD","BK1584","IE00BZ08YT58.USD","BK1205","02628","LU0052750758.USD","LU1226288253.USD","LU0880133367.SGD","KURE","LU0588546209.SGD","SG9999003461.SGD","IE0032431581.USD","BK1589","03692","HK0000286598.CNH","LU1226288170.HKD","IE0008368742.USD","LU0326950275.SGD","LU1808992512.USD","BK1537","IE00B3M56506.USD","LU3063872942.SGD","LU2039709279.SGD","LU0164865239.USD","LU2097828557.USD","FLHK","00659","SG9999004220.SGD","BK1191","LU1226287529.USD","KCAI","LU0501845795.SGD","BK1521","FDN","LU2097828631.EUR","LU1226287875.USD","VXUS","LU0173614495.USD","01133","IE00B543WZ88.USD","03933","LU0871576103.HKD","LU0314109678.HKD","BK1583","LU1152091168.USD","LU0708995583.HKD","BK1546","IE0008369823.USD","LU1960683339.HKD","LU1328277881.USD","BK1550","LU0072913022.USD","LU2097828805.USD","01093","SG9999012744.USD","BK4585","LU0169518387.USD","BK4588","01191","BK1147","LU1008478684.HKD","IE00BZ08YS42.EUR","LU0140636845.USD","SG9999012728.SGD","BK1230","LU0531971595.HKD","SG9999012736.USD","LU0287142896.SGD","HK0000165453.HKD","IE00BZ08YR35.GBP","LU0211977185.USD","LU1807302812.USD","LU1951186391.HKD","IE00B5MMRT66.SGD","LU0067412154.USD","IE00B031HY20.USD","LU0039217434.USD","LU1046422090.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669558491","title":"CSPC Pharmaceutical Says Phase III Trial of Becotatug Achieves Positive Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669558491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669558491?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:01","pubTimestamp":1790262116,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical Says Phase III Trial Of Becotatug Achieves Positive Topline ResultsSept 24 (Reuters)-CSPC PHARMACEUTICAL GROUP LIMITED1093.HK:PHASE III TRIAL OF BECOTATUG (JMT101) WITH OSIMERTINIB ACHIEVES POSITIVE TOPLINE RESULTSFurther company coverage:1093.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0880133367.SGD","LU0315179316.USD","LU1328277881.USD","SG9999004220.SGD","LU1226287529.USD","BK1515","IE0008369823.USD","LU1226287875.USD","LU1152091754.HKD","IE00B031HY20.USD","01093","LU1813983027.USD","KURE","LU0501845795.SGD","IE00BZ08YR35.GBP","IE0008368742.USD","LU0140636845.USD","LU1993786604.SGD","LU0067412154.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","LU1226287792.SGD","BK1191","HK0000165453.HKD","LU1226288170.HKD","LU1008478684.HKD","LU0072913022.USD","LU0326950275.SGD","LU2039709279.SGD","IE00BZ08YT58.USD","LU1226288253.USD","LU1951186391.HKD","LU1960683339.HKD","LU1152091168.USD","IE00B543WZ88.USD","LU1807302812.USD","BK1521","LU0314109678.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669498067","title":"CSPC Pharma's Phase III Trial of Lung Cancer Drug Combo Achieves Positive Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669498067","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669498067?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:55","pubTimestamp":1790254529,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group's  phase III trial of Becotatug in combination with osimertinib met its primary endpoint at a pre-specified interim analysis and achieved positive topline results.The drug combination was being tested for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.Compared with platinum-based chemotherapy in combination with pemetrexed, the treatment combination significantly prolonged the progression-free survival of patients and showed a trend of benefit in overall survival.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1960683339.HKD","KURE","LU0314109678.HKD","LU1951186391.HKD","01093","LU1226287529.USD","LU0880133367.SGD","IE00BZ08YS42.EUR","LU0072913022.USD","LU0315179316.USD","IE00BZ08YR35.GBP","IE0008368742.USD","IE00B543WZ88.USD","IE0008369823.USD","LU2039709279.SGD","LU1226288253.USD","LU1807302812.USD","BK1521","HK0000165453.HKD","SG9999004220.SGD","LU1008478684.HKD","LU0140636845.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU1813983027.USD","LU0501845795.SGD","LU1152091754.HKD","LU1328277881.USD","LU1993786604.SGD","LU0067412154.USD","LU1226287792.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU1152091168.USD","LU1226288170.HKD","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669261498","title":"WuXi Biologics - Wuxi Mashan Site Passes Two-Week FDA Gmp Inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=2669261498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669261498?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:48","pubTimestamp":1790254108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G0DO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320764599.SGD","LU0516422440.USD","LU0181495838.USD","BK1610","LU0823426480.USD","LU0979878070.USD","LU0708995153.HKD","BK1521","LU0359202008.SGD","LU0417516902.SGD","LU0348825331.USD","LU0516422366.SGD","LU0823426308.USD","BK1576","LU0029874061.USD","LU0029874905.USD","LU0417516738.SGD","02269","LU0043850808.USD","LU1880383366.USD","BK1589","SG9999002463.SGD","LU0348827113.USD","LU0634319403.HKD","LU0051755006.USD","LU0348735423.USD","LU0327786744.USD","LU1242518857.USD","LU0326950275.SGD","LU0128522744.USD","KURE","LU0052750758.USD","BK1141","LU0140636845.USD","LU0456827905.SGD","LU0516423174.USD","LU0708995583.HKD","LU3063872942.SGD","LU1242518931.SGD","SG9999002562.SGD","LU0856984785.SGD","LU0320764243.SGD","LU0359201612.USD","LU1794554557.SGD","LU0819121731.USD","LU1688375341.USD","LU0588546209.SGD","IE00B0JY6N72.USD","LU1720050803.USD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183769643","title":"CSPC Pharma's JMT101 Combined with Osimertinib Achieves Positive Topline Results in Phase III Trial for First-Line Treatment of EGFR ex20ins NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1183769643","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183769643?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:28","pubTimestamp":1790252894,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that the Phase III clinical trial of its developed becotatug (JMT101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","KURE","LU1226287529.USD","LU1226288253.USD","LU2039709279.SGD","LU0501845795.SGD","SG9999004220.SGD","LU0326950275.SGD","MDTX","LU1152091168.USD","LU1008478684.HKD","LU1226287875.USD","IE0008368742.USD","LU1960683339.HKD","BK1515","IE00B031HY20.USD","LU0140636845.USD","LU0880133367.SGD","LU1152091754.HKD","PSYK","IE0008369823.USD","BK1191","IE00B543WZ88.USD","BMED","01093","LU0072913022.USD","LU1328277881.USD","LU0067412154.USD","LU0314109678.HKD","LU1226287792.SGD","LU1951186391.HKD","LU1807302812.USD","LU1993786604.SGD","LU1813983027.USD","HK0000165453.HKD","IBBQ","LU0315179316.USD","IBBJ","IE00BZ08YT58.USD","BK1521","LU1226288170.HKD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669460157","title":"CSPC Pharmaceutical - Phase Iii Trial of Becotatug (Jmt101) with Osimertinib Achieves Positive Topline Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669460157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669460157?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:08","pubTimestamp":1790251730,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1521","LU1960683339.HKD","IE0008368742.USD","LU1993786604.SGD","IE00B543WZ88.USD","LU0067412154.USD","LU1226288170.HKD","LU1226287529.USD","LU1226287875.USD","LU0880133367.SGD","LU1152091168.USD","LU0314109678.HKD","LU1226288253.USD","BK1515","LU0072913022.USD","LU1152091754.HKD","LU1813983027.USD","LU1807302812.USD","LU0140636845.USD","LU1226287792.SGD","IE00BZ08YT58.USD","LU0501845795.SGD","BK1191","IE00BZ08YS42.EUR","LU1951186391.HKD","SG9999004220.SGD","LU0315179316.USD","HK0000165453.HKD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU1008478684.HKD","LU1328277881.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","01093","LU2039709279.SGD","IE0008369823.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669246984","title":"CSPC Pharm Begins Phase III Breast Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669246984","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669246984?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:42","pubTimestamp":1790242928,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) officially initiated a phase III trial of docetaxel for injection at the first centre in China, according to a Thursday bourse filing.The study will evaluate the safety and efficacy of the drug in patients with advanced breast cancer, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0072913022.USD","LU0315179316.USD","LU0501845795.SGD","LU1226288170.HKD","LU0067412154.USD","LU1226287875.USD","LU0326950275.SGD","LU1960683339.HKD","LU1993786604.SGD","IE00B5MMRT66.SGD","IE00B031HY20.USD","IE00BZ08YT58.USD","LU1226287792.SGD","01093","LU1152091754.HKD","LU1951186391.HKD","IE00BZ08YS42.EUR","IE0008369823.USD","LU0140636845.USD","HK0000165453.HKD","KURE","BK1515","LU1226287529.USD","LU0314109678.HKD","LU1152091168.USD","LU1813983027.USD","LU1008478684.HKD","SG9999004220.SGD","BK1191","LU1807302812.USD","IE00B543WZ88.USD","BK1521","IE0008368742.USD","LU2039709279.SGD","IE00BZ08YR35.GBP","LU1226288253.USD","LU1328277881.USD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669465671","title":"CSPC Pharmaceutical - Pharma Initiates Phase Iii Trial of Hb1801 for Advanced Breast Cancer in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2669465671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669465671?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:01","pubTimestamp":1790240462,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G0P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1328277881.USD","IE00BZ08YS42.EUR","LU1226288253.USD","LU1960683339.HKD","LU0315179316.USD","BK1191","BK1515","LU1226287529.USD","IE00B543WZ88.USD","IE00B031HY20.USD","IE00B5MMRT66.SGD","IE0008369823.USD","LU1226288170.HKD","LU1951186391.HKD","LU1807302812.USD","LU0140636845.USD","HK0000165453.HKD","SG9999004220.SGD","LU0314109678.HKD","LU1152091754.HKD","LU1813983027.USD","LU1993786604.SGD","LU1226287875.USD","01093","LU2039709279.SGD","IE00BZ08YT58.USD","LU1152091168.USD","LU1008478684.HKD","BK1521","LU0072913022.USD","LU0880133367.SGD","LU0501845795.SGD","LU0326950275.SGD","IE00BZ08YR35.GBP","IE0008368742.USD","LU1226287792.SGD","KURE","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669633064","title":"CSPC Pharmaceutical Group Stock Slips 3.2% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669633064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669633064?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:30","pubTimestamp":1790238600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slid 3.2% to 9.34 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.3% to 24761.13.This was the stock's second consecutive day of losses.CSPC Pharmaceutical Group Ltd. closed 15% below its 52-week high of HK$10.96, which the company achieved Jan. 30.The stock underperformed when compared to some of its competitors, as Sino Biopharmaceutical Ltd. fell 1.8%, SSY Group Ltd. remained unchanged, and United Laboratories International Holdings Ltd. fell 2.8%.Trading volume totaled 78.5 million shares, compared to the 50-day average of 95.3 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","KURE","LU1226287529.USD","LU1226288253.USD","LU2039709279.SGD","LU0501845795.SGD","SG9999004220.SGD","LU0326950275.SGD","LU1152091168.USD","LU1008478684.HKD","LU1226287875.USD","IE0008368742.USD","LU1960683339.HKD","BK1515","IE00B031HY20.USD","LU0140636845.USD","LU0880133367.SGD","LU1152091754.HKD","IE0008369823.USD","BK1191","IE00B543WZ88.USD","LU0072913022.USD","01093","LU1328277881.USD","LU1951186391.HKD","LU0067412154.USD","LU0314109678.HKD","LU1226287792.SGD","LU1807302812.USD","LU1993786604.SGD","LU1813983027.USD","HK0000165453.HKD","LU0315179316.USD","IE00BZ08YT58.USD","BK1521","LU1226288170.HKD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463305","title":"Wuxi Biologics (Cayman) Stock Slips 1.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463305","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669463305?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:30","pubTimestamp":1790238600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. shed 1.7% to 51.90 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.3% to 24761.13.Wuxi Biologics  Inc. closed 4.7% short of its 52-week high of HK$54.45, which the company reached Aug. 26.Trading volume totaled 13.3 million shares, compared to the 50-day average of 35.5 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0181495838.USD","LU0348827113.USD","BK1610","LU0572944931.SGD","LU0039217434.USD","LU0456846285.SGD","LU0823426480.USD","BK1576","KURE","LU0634319403.HKD","LU0417516738.SGD","LU0128526141.USD","LU0051755006.USD","LU0052750758.USD","LU0320764599.SGD","LU0327786744.USD","LU0348735423.USD","LU0417516902.SGD","LU0708995153.HKD","LU0348825331.USD","LU1880383366.USD","SG9999002463.SGD","LU0540923850.HKD","LU1242518931.SGD","LU0043850808.USD","LU0320764243.SGD","LU2039709279.SGD","02269","LU1794554557.SGD","LU1720050803.USD","LU0359202008.SGD","LU0456827905.SGD","LU0856984785.SGD","SG9999002562.SGD","LU0307460666.USD","LU0979878070.USD","LU1242518857.USD","LU0516422366.SGD","LU0516423091.SGD","BK1141","LU0128522744.USD","BK1589","LU0359201612.USD","LU0516422952.EUR","LU0819121731.USD","BK1521","LU0823426308.USD","IE00B0JY6N72.USD","LU0516422440.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135063406","title":"Hong Kong Healthcare Stocks Show Resilience as CXO Sector Takes the Lead, Key ETF Closes Higher Despite Market Downturn, GenScript Hits Five-Year High, and Two Key Questions Emerge","url":"https://stock-news.laohu8.com/highlight/detail?id=1135063406","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135063406?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:20","pubTimestamp":1790162451,"startTime":"0","endTime":"0","summary":"On September 23rd, healthcare stocks once again bucked the broader market trend in Hong Kong, performing strongly against a widespread decline. The CXO sector, situated upstream in the AI drug...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4588","WX","BK4585","159718","FDN","KURE","159137","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100645757","title":"INNOVENT BIO Posts Robust Growth on Dual Momentum From Oncology and Integrated Product Lines","url":"https://stock-news.laohu8.com/highlight/detail?id=1100645757","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100645757?lang=en_us&edition=fundamental","pubTime":"2026-09-23 18:10","pubTimestamp":1790158246,"startTime":"0","endTime":"0","summary":"INNOVENT BIO has delivered another period of strong financial performance, with total revenue for the first half of 2026 reaching RMB 8.618 billion, a year-on-year increase of 44.8%. Product revenue...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","09939","LU1188198961.HKD","KURE","LU2242644610.SGD","LU2097828714.EUR","BK1583","LU0502904849.HKD","BK1515","LU2097828557.USD","LU0326950275.SGD","LU0244354667.USD","BK1589","LU2097828474.EUR","BK1574","LU2097828805.USD","LU0607220059.USD","159938","LU2328871848.SGD","HK0000165453.HKD","LU0455707207.USD","LU0463099449.HKD","LU2488822045.USD","BK1161","LU0149534421.HKD","LU1969619763.USD","LU2097828631.EUR","LU1831875114.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669092751","title":"Innovent to Present Phase 3 Interim Data for Cldn18.2 ADC Ibi343 in Third-Line Gastric Cancer at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669092751","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669092751?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:49","pubTimestamp":1790153370,"startTime":"0","endTime":"0","summary":"Innovent to present phase 3 interim data for CLDN18.2 ADC IBI343 in third-line gastric cancer at ESMO 2026Innovent Biologics scheduled new clinical readouts for its next-generation immuno-oncology and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDLc9g4S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","LU2097828805.USD","LU0463099449.HKD","LU1188198961.HKD","LU2097828557.USD","LU0607220059.USD","LU1831875114.USD","KURE","LU2097828474.EUR","LU0326950275.SGD","LU0149534421.HKD","LU2242644610.SGD","BK1589","01911","LU2488822045.USD","LU2097828714.EUR","LU2328871848.SGD","HK0000165453.HKD","LU0455707207.USD","LU1969619763.USD","01801","BK1161","LU0244354667.USD","BK1583","BK1147","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114841719","title":"China's Innovative Drugs Take Center Stage at Global Lung Cancer Conference, with ADC Therapies Advancing to Earlier Treatment Lines","url":"https://stock-news.laohu8.com/highlight/detail?id=1114841719","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114841719?lang=en_us&edition=fundamental","pubTime":"2026-09-23 09:56","pubTimestamp":1790128580,"startTime":"0","endTime":"0","summary":"Sinolink Securities Co., Ltd. has released a research report noting that as multiple Chinese innovative drugs release dense clinical data, with results in PD-1 plus bispecific antibodies, ADCs, and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0201","KURE","BK0028","BK0188","BK0012","BK0276","600109","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120742791","title":"Hong Kong Stocks Open Mixed: Hang Seng Edges Down 0.09%, Tech Index Flat, Memory Chip Plays Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1120742791","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120742791?lang=en_us&edition=fundamental","pubTime":"2026-09-23 09:36","pubTimestamp":1790127394,"startTime":"0","endTime":"0","summary":"US equities delivered a mixed performance on Tuesday, with retreating oil prices lifting overall market sentiment. The Dow opened higher and briefly extended gains before reversing course under...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02837","LU2328871848.SGD","09067","MCHmain","BK1500","KURE","LU1969619763.USD","07300","HSI","07200","HSTECH","03088","BK1583","LU0228659784.USD","LU0588546209.SGD","02833","07552","03423","03417","BK1161","LU0307460666.USD","LU1251922891.USD","LU0828237510.HKD","82800","83115","BK1588","513600","03032","02800","03419","HHImain","07226","688235","03067","03033","06160","03037","09088","HTImain","09115","03115","HSImain","LU1303224171.USD","LU1719994722.HKD","07500","ONC","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}